HRD refers to the impairment or deficiency in the ability of cancer cells to repair DNA damage through the homologous recombination pathway. This pathway is crucial for the repair of double-stranded DNA breaks. By identifying HRD status in ovarian cancer By identifying HRD status in ovarian cancer, clinicians can better personalize treatment options and determine the most appropriate therapeutic interventions for patients, potentially improving treatment outcomes.

GC Genome’s new tHRD(transcriptional HRD) test can more accurately detect patients who are responsive to drugs compared to the existing DNA-based HRD testing method. Our approach focused on a novel but widespread transcriptional mechanism by which HRD arises independently of BRCA1/2 mutations. This test can serve as a companion diagnostic for PARP inhibitors, providing valuable guidance in treatment decisions.